These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6323321)

  • 41. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
    Campoli-Richards DM; Brogden RN
    Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.
    Fass RJ
    Antimicrob Agents Chemother; 1981 Feb; 19(2):361-3. PubMed ID: 6289732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. II. Antibacterial properties.
    Angehrn P; Arisawa M
    J Antibiot (Tokyo); 1982 Nov; 35(11):1584-9. PubMed ID: 6298168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
    Sorg TB; Cynamon MH
    J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 47. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study of in vitro activity of 3 cephalosporins and their combination with 2 beta-lactamase inhibitors against 4 enterobacteria strains producing extended spectrum beta-lactamase].
    Cattoen C; Duflos D; Bouillet L; Chatelain C; Mazars E
    Pathol Biol (Paris); 1997 May; 45(5):425-9. PubMed ID: 9296097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An in-vitro and in-vivo comparison of the activity of beta-lactamase inhibitor combinations with imipenem and cephalosporins against Escherichia coli producing TEM-1 or TEM-2 beta-lactamase.
    Cherubin CE; Eng RH; Smith SM; Tan EN
    J Antimicrob Chemother; 1991 Jul; 28(1):61-70. PubMed ID: 1769944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.
    Yu Y; Zhou W; Chen Y; Ding Y; Ma Y
    Chin Med J (Engl); 2002 Oct; 115(10):1479-82. PubMed ID: 12490091
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Sensitivity to FL 1060 (mecilliman) of E. coli and Klebsiella pneumoniae isolated from bile (author's transl)].
    Deguchi K
    Jpn J Antibiot; 1980 Mar; 33(3):329-32. PubMed ID: 6249943
    [No Abstract]   [Full Text] [Related]  

  • 53. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin.
    Vaara M; Siikanen O; Apajalahti J; Frimodt-Møller N; Vaara T
    J Antimicrob Chemother; 2010 May; 65(5):942-5. PubMed ID: 20167589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibacterial activity of ampicillin alone and in combination with sulbactam correlated with beta-lactamase production.
    Chao HP; Ho SW; Luh KT; Hsieh WC
    Taiwan Yi Xue Hui Za Zhi; 1987 Mar; 86(3):241-7. PubMed ID: 3037003
    [No Abstract]   [Full Text] [Related]  

  • 55. [The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro].
    Quan JJ; Wang Y; Ji JS; Wang YF; Wang HP; Xu YC; Yu YS
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1459-64. PubMed ID: 27266357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of sulbactam combinations against Escherichia coli isolates with known amounts of TEM-1 beta-lactamase.
    Livermore DM
    J Antimicrob Chemother; 1992 Feb; 29(2):222-4. PubMed ID: 1506339
    [No Abstract]   [Full Text] [Related]  

  • 57. Mecillinam-ampicillin synergism in experimental Enterobacteriaceae meningitis.
    Scheld WM; Fink FN; Fletcher DD; Sande MA
    Antimicrob Agents Chemother; 1979 Sep; 16(3):271-6. PubMed ID: 228591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory activity and bactericidal kinetics of mecillinam/ampicillin combinations against Enterobacteriaceae, Pseudomonas and Acinetobacter.
    Fuglesang JE; Bergan T; Bielecki T; Naterstad A; Namork E
    Infection; 1981; 9(6):290-5. PubMed ID: 6277795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.